Journal article
Treatment-refractory autoimmune sensorineural hearing loss: Response to infliximab
Ear, nose, & throat journal, v 90(1), pp 23-28
01 Jan 2011
PMID: 21229506
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
We conducted a retrospective study to assess the effects of infliximab, a chimeric monoclonal antibody, on hearing in patients with autoimmune sensorineural hearing loss who had previously not responded to steroid therapy and/or treatment with other immunosuppressive drugs such as methotrexate and cyclophosphamide. We reviewed the records of 8 such patients. Our objective measures of outcome were pure-tone averages at 500, 1,000, 2,000, and 3,000 Hz and speech discrimination scores. At the completion of treatment, no patient exhibited a positive response to infliximab therapy by objective measurements, and only 1 patient (12.5%) reported subjective improvement.
Metrics
Details
- Title
- Treatment-refractory autoimmune sensorineural hearing loss: Response to infliximab
- Creators
- Yi-Chun Liu - Case Western Reserve UniversityRene Rubin - Drexel UniversityRobert T. Sataloff - Drexel University
- Publication Details
- Ear, nose, & throat journal, v 90(1), pp 23-28
- Publisher
- Sage
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine; General Internal Medicine
- Web of Science ID
- WOS:000286867500006
- Scopus ID
- 2-s2.0-79751488501
- Other Identifier
- 991019167966104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Otorhinolaryngology